Protara Therapeutics, Inc. (TARA) NASDAQ
5.44
+0.31(+6.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.44
+0.31(+6.04%)
Currency In USD
| Previous Close | 5.13 |
| Open | 5.16 |
| Day High | 5.45 |
| Day Low | 5.1 |
| 52-Week High | 7.82 |
| 52-Week Low | 2.77 |
| Volume | 643,745 |
| Average Volume | 997,020 |
| Market Cap | 209.93M |
| PE | -4.06 |
| EPS | -1.34 |
| Moving Average 50 Days | 5.71 |
| Moving Average 200 Days | 4.92 |
| Change | 0.31 |
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
GlobeNewswire Inc.
Feb 23, 2026 10:05 PM GMT
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
GlobeNewswire Inc.
Jan 22, 2026 1:00 PM GMT
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the co
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026